Insider Buy/Sell Details for the Biotechnology Industry — April 2026
Ratio0.1:1
Daily Buy & Sell Volume
Transactions (1153)
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
600
Price
$580.06
Total Value
$348.03K
Shares Held After
40,513
% of Holdings
1.5%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
1,099
Price
$579.08
Total Value
$636.41K
Shares Held After
41,113
% of Holdings
2.6%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
1,781
Price
$578.11
Total Value
$1.03M
Shares Held After
42,212
% of Holdings
4.0%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
1,707
Price
$576.98
Total Value
$984.91K
Shares Held After
43,993
% of Holdings
3.7%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
1,410
Price
$575.99
Total Value
$812.15K
Shares Held After
45,700
% of Holdings
3.0%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
736
Price
$574.86
Total Value
$423.09K
Shares Held After
47,110
% of Holdings
1.5%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
1,644
Price
$574.06
Total Value
$943.75K
Shares Held After
47,846
% of Holdings
3.3%
UNITED THERAPEUTICS Corp (UTHR)
ROTHBLATT MARTINE A — Director
Shares
523
Price
$572.48
Total Value
$299.41K
Shares Held After
49,490
% of Holdings
1.0%
Travere Therapeutics, Inc. (TVTX)
ROTE WILLIAM E. — Chief Research Officer
Shares
9,100
Price
$39.09
Total Value
$355.72K
Shares Held After
113,987
% of Holdings
7.4%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
21
Price
$173.04
Total Value
$3.63K
Shares Held After
10,666
% of Holdings
0.2%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
249
Price
$172.49
Total Value
$42.95K
Shares Held After
10,687
% of Holdings
2.3%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
257
Price
$171.62
Total Value
$44.11K
Shares Held After
10,936
% of Holdings
2.3%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
75
Price
$170.58
Total Value
$12.79K
Shares Held After
11,193
% of Holdings
0.7%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
105
Price
$169.52
Total Value
$17.80K
Shares Held After
11,268
% of Holdings
0.9%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
101
Price
$168.64
Total Value
$17.03K
Shares Held After
11,373
% of Holdings
0.9%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
141
Price
$167.42
Total Value
$23.61K
Shares Held After
11,474
% of Holdings
1.2%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
20
Price
$166.32
Total Value
$3.33K
Shares Held After
11,615
% of Holdings
0.2%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
31
Price
$165.70
Total Value
$5.14K
Shares Held After
11,635
% of Holdings
0.3%
SANGAMO THERAPEUTICS, INC (SGMO)
Davis Gregory D — Head of Research & Technology
Shares
69,827
Price
$0.25
Total Value
$17.69K
Shares Held After
115,284
% of Holdings
37.7%
Dyne Therapeutics, Inc. (DYN)
Kersten Dirk — Director
Shares
2,652
Price
$20.00
Total Value
$53.05K
Shares Held After
4,196,573
% of Holdings
0.1%
BioNTech SE (BNTX)
Poetting Sierk — Chief Operating Officer
Shares
50,000
Price
$110.56
Total Value
$5.53M
Shares Held After
399,387
% of Holdings
11.1%
Aditxt, Inc. (ADTX)
HRT FINANCIAL LP — 10% Owner
Shares
11,982
Price
$0.30
Total Value
$3.59K
Shares Held After
121,592
% of Holdings
9.0%
Nasus Pharma Ltd (NSRX)
Teleman Dan Benjamin — Director
Shares
2,900
Price
$3.76
Total Value
$10.90K
Shares Held After
156,991
% of Holdings
1.8%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
59,663
Price
$19.68
Total Value
$1.17M
Shares Held After
1,285,704
% of Holdings
4.4%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
1,485
Price
$19.68
Total Value
$29.22K
Shares Held After
11,663
% of Holdings
11.3%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
150,942
Price
$19.68
Total Value
$2.97M
Shares Held After
5,260,179
% of Holdings
2.8%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
75,866
Price
$19.68
Total Value
$1.49M
Shares Held After
1,738,617
% of Holdings
4.2%
Hepion Pharmaceuticals, Inc. (HEPA)
Purcell Michael J. — Director
Shares
1,250,000
Price
$0.04
Total Value
$50.00K
Shares Held After
1,250,000
% of Holdings
100.0%
Hepion Pharmaceuticals, Inc. (HEPA)
Appajosyula Sireesh — Director
Shares
1,250,000
Price
$0.04
Total Value
$50.00K
Shares Held After
1,250,000
% of Holdings
100.0%
Hepion Pharmaceuticals, Inc. (HEPA)
LoPriore Vincent S — Director
Shares
1,250,000
Price
$0.04
Total Value
$50.00K
Shares Held After
6,250,000
% of Holdings
20.0%
Hepion Pharmaceuticals, Inc. (HEPA)
Stetz Gary S. — Director
Shares
1,250,000
Price
$0.04
Total Value
$50.00K
Shares Held After
1,250,000
% of Holdings
100.0%
Hepion Pharmaceuticals, Inc. (HEPA)
LoPriore Vincent S — Director
Shares
5,000,000
Price
$0.04
Total Value
$200.00K
Shares Held After
5,000,000
% of Holdings
100.0%
Prelude Therapeutics Inc (PRLD)
Bonita David P — Director
Shares
1,126,126
Price
$4.44
Total Value
$5.00M
Shares Held After
1,126,126
% of Holdings
100.0%
Prelude Therapeutics Inc (PRLD)
Bonita David P — Director
Shares
1,689,189
Price
$4.44
Total Value
$7.50M
Shares Held After
11,808,945
% of Holdings
14.3%
Prelude Therapeutics Inc (PRLD)
ORBIMED ADVISORS LLC — Director
Shares
1,126,126
Price
$4.44
Total Value
$5.00M
Shares Held After
1,126,126
% of Holdings
100.0%
Prelude Therapeutics Inc (PRLD)
ORBIMED ADVISORS LLC — Director
Shares
1,689,189
Price
$4.44
Total Value
$7.50M
Shares Held After
11,808,945
% of Holdings
14.3%
PTC THERAPEUTICS, INC. (PTCT)
Klein Matthew B. — Director
Shares
2,850
Price
$70.91
Total Value
$202.09K
Shares Held After
394,070
% of Holdings
0.7%
SANGAMO THERAPEUTICS, INC (SGMO)
Dubois-Stringfellow Nathalie — SVP-CHIEF DEVELOPMENT OFFICER
Shares
345,942
Price
$0.26
Total Value
$89.18K
Shares Held After
332,769
% of Holdings
51.0%
Dyne Therapeutics, Inc. (DYN)
Kersten Dirk — Director
Shares
8,300
Price
$20.01
Total Value
$166.12K
Shares Held After
4,199,225
% of Holdings
0.2%
Allogene Therapeutics, Inc. (ALLO)
Yoshiyama Annie — SVP, Finance
Shares
9,586
Price
$2.31
Total Value
$22.14K
Shares Held After
124,517
% of Holdings
7.1%
Aditxt, Inc. (ADTX)
HRT FINANCIAL LP — 10% Owner
Shares
72,912
Price
$0.33
Total Value
$24.06K
Shares Held After
133,574
% of Holdings
54.6%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
605
Price
$20.05
Total Value
$12.13K
Shares Held After
1,345,367
% of Holdings
0.0%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
15
Price
$20.05
Total Value
$300.75
Shares Held After
13,148
% of Holdings
0.1%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
1,530
Price
$20.05
Total Value
$30.68K
Shares Held After
5,411,121
% of Holdings
0.0%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
769
Price
$20.05
Total Value
$15.42K
Shares Held After
1,814,483
% of Holdings
0.0%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
56,228
Price
$19.51
Total Value
$1.10M
Shares Held After
1,345,972
% of Holdings
4.0%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
1,398
Price
$19.51
Total Value
$27.27K
Shares Held After
13,163
% of Holdings
9.6%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
142,253
Price
$19.51
Total Value
$2.78M
Shares Held After
5,412,651
% of Holdings
2.6%
Dyne Therapeutics, Inc. (DYN)
Rhodes Jason P — Director
Shares
71,499
Price
$19.51
Total Value
$1.39M
Shares Held After
1,815,252
% of Holdings
3.8%
Clene Inc. (CLNN)
Ugwumba Chidozie — 10% Owner
Shares
61,345
Price
$6.14
Total Value
$376.66K
Shares Held After
297,066
% of Holdings
17.1%
Showing 251–300 of 1153 transactions (page 6 of 24)